摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-ene-1-one | 166196-86-7

中文名称
——
中文别名
——
英文名称
1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-ene-1-one
英文别名
1-(5-bromopyridin-3-yl)-3-(dimethylamino)-2-propen-1-one;1-(5-bromopyridin-3-yl)-3-dimethylamino-propenone;1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-en-1-one
1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-ene-1-one化学式
CAS
166196-86-7
化学式
C10H11BrN2O
mdl
——
分子量
255.114
InChiKey
GLDHCTXOXXKUEB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    330.5±42.0 °C(Predicted)
  • 密度:
    1.411±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    33.2
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211
    申请人:Bist Shanta
    公开号:US20120101100A1
    公开(公告)日:2012-04-26
    Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    本文描述了化合物公式(I)及其药学上可接受的盐。还描述了它们的制备过程,包含它们的制药组合物,它们作为药物的用途以及它们在治疗细菌感染方面的用途。
  • Nicotinamide derivative or salt thereof
    申请人:Fujiwara Hideyasu
    公开号:US08772320B2
    公开(公告)日:2014-07-08
    An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
    本发明的目的是提供一种具有优异Syk抑制活性的化合物和药物组合物。本发明提供了以下式子(I)所表示的烟酰胺衍生物(其中R1表示卤素原子;R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基,每个都可以选择性地具有至少一个取代基;R3表示芳基或杂环基,每个都可以选择性地具有至少一个取代基;R4和R5各自独立地表示氢原子;且R2和R4可以与它们结合的氮原子一起选择性地形成一个带有至少一个取代基的环状氨基团)或其盐,以及用于治疗Syk相关疾病的药物组合物,其包括该烟酰胺衍生物或其盐。
  • NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
    申请人:FUJIWARA Hideyasu
    公开号:US20130116430A1
    公开(公告)日:2013-05-09
    An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
    本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物(其中R1表示卤素原子;R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基,每种均可选地具有至少一个取代基;R3表示芳基或杂环基,每种均可选地具有至少一个取代基;R4和R5各自独立地表示氢原子;且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团)或其盐,并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
  • AMIDE DERIVATIVE
    申请人:Nippon Shinyaku Co., Ltd.
    公开号:EP1533304B1
    公开(公告)日:2009-11-04
  • AMIDE DERIVATIVE AND MEDICINE
    申请人:Nippon Shinyaku Co., Ltd.
    公开号:EP1702917B1
    公开(公告)日:2017-08-02
查看更多